Guide

Retatrutide vs Tirzepatide

Retatrutide and tirzepatide are the two most-discussed next-generation GLP-1 peptides. They're related but not the same, and the right choice depends on what you're studying and your tolerance for a newer compound. Here's the honest comparison.

The core difference: dual vs triple agonist

Tirzepatide is a dual agonist — it activates the GIP and GLP-1 receptors. Retatrutide is a triple agonist, adding glucagon-receptor activity on top. In research, that third pathway is associated with larger effects on body weight, which is why retatrutide gets so much attention as the "next step."

What the research suggests

Across published trials, tirzepatide has a long, well-documented track record and a predictable response curve. Retatrutide is newer, with trial data pointing to larger average weight reductions but a shorter real-world history. More potency can also mean more attention to slow titration.

Dosing cadence

Both are dosed weekly and titrated up over time. Our dose-duration calculator walks the standard titration ladders for each so you can estimate how long a given amount lasts at your dose.

Cost

Tirzepatide generally sits at a lower price point than retatrutide, which carries a premium as the newest compound. See live pricing on the tirzepatide and retatrutide product pages.

How to choose

If you want the established, lower-cost option with the deepest data, tirzepatide is the workhorse. If you're specifically interested in the triple-agonist mechanism and the larger effect sizes seen in research, retatrutide is the frontier. Either way, insist on a verifiable COA — potency claims only matter if the batch is tested.

For research use only. Not for human consumption. Nothing here is medical advice.